Table 1.
Ranking and characteristics of the top-cited original studies on cysticercosis and neurocysticercosis.
| Overall rank | Article rank | Publication | Topic | Country of origin | N citations | Citation density | |
|---|---|---|---|---|---|---|---|
| 1st author | Last author | ||||||
| 1 | 1 | Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis. 1989;159(1):50-59. doi:10.1093/infdis/159.1.50 | Diagnosis, laboratory parameters | USA | USA | 638 | 20.58 |
| 4 | 2 | Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med. 1985;145(3):442-445. | Clinical presentation | Mexico | Mexico | 367 | 10.49 |
| 5 | 3 | Osborn AG, Preece MT. Intracranial cysts: radiologic-pathologic correlation and imaging approach. Radiology. 2006;239(3):650-664. doi:10.1148/radiol.2393050823 | Imaging | USA | USA | 346 | 24.71 |
| 7 | 4 | Schantz PM, Moore AC, Muñoz JL, et al Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med. 1992;327(10):692-695. doi:10.1056/NEJM199209033271004 | Clinical presentation | USA | USA | 308 | 11 |
| 13 | 5 | Garcia HH, Pretell EJ, Gilman RH, et al A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350(3):249-258. doi:10.1056/NEJMoa031294 | Therapeutics | Peru | Peru | 255 | 15.94 |
| 14 | 6 | McCormick GF, Zee CS, Heiden J. Cysticercosis cerebri. Review of 127 cases. Arch Neurol. 1982;39(9):534-539. doi:10.1001/archneur.1982.00510210004002 | Clinical presentation | USA | USA | 248 | 6.53 |
| 15 | 7 | Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med. 1984;310(16):1001-1007. doi:10.1056/NEJM198404193101601 | Therapeutics | Mexico | Mexico | 246 | 6.83 |
| 16 | 8 | Johnson KS, Harrison GB, Lightowlers MW, et al Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature. 1989;338(6216):585-587. doi:10.1038/338585a0 | Therapeutics | Australia | Australia | 240 | 24 |
| 17 | 9 | Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. 1992;42(2):389-392. doi:10.1212/wnl.42.2.389 | Central nervous system & epilepsy |
Peru | Peru | 239 | 8.54 |
| 18 | 10 | Wilson M, Bryan RT, Fried JA, et al Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis. 1991;164(5):1007-1009. doi:10.1093/infdis/164.5.1007 | Diagnosis, laboratory parameters | USA | USA | 228 | 7.76 |
| 21 | 11 | Bowles J, McManus DP. Genetic characterization of the Asian Taenia, a newly described taeniid cestode of humans. Am J Trop Med Hyg. 1994;50(1):33-44 | Parasitology | Australia | Australia | 206 | 7.92 |
| 22 | 12 | Dorny P, Phiri IK, Vercruysse J, et al A Bayesian approach for estimating values for prevalence and diagnostic test characteristics of porcine cysticercosis. Int J Parasitol. 2004;34(5):569-576. doi:10.1016/j.ijpara.2003.11.014 | Epidemiology | Belgium | Belgium | 200 | 12.5 |
| 24 | 13 | Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med. 1990;150(2):325-327 | Central nervous system & epilepsy |
Mexico | Mexico | 195 | 6.5 |
| 27 | 14 | Garcia HH, Gilman R, Martinez M, et al Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG). Lancet. 1993;341(8839):197-200. doi:10.1016/0140-6736(93)90064-n | Central nervous system & epilepsy |
Peru | Peru | 174 | 6.44 |
| 28 | 15 | Yamasaki H, Allan JC, Sato MO, et al DNA differential diagnosis of teniasis and cysticercosis by multiplex PCR. J Clin Microbiol. 2004;42(2):548-553. doi:10.1128/JCM.42.2.548-553.2004 | Diagnosis, laboratory parameters | Japan | Japan | 168 | 10.5 |
| 29 | 16 | Sotelo J, del Brutto OH, Penagos P, et al Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol. 1990;237(2):69-72. doi:10.1007/BF00314663 | Therapeutics | Mexico | Mexico | 164 | 5.47 |
| 31 | 17 | Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med. 1992;327(10):696-701. doi:10.1056/NEJM199209033271005 | Central nervous system & epilepsy |
Mexico | Mexico | 161 | 6.71 |
| 33 | 18 | Sarti E, Schantz PM, Plancarte A, et al Prevalence and risk factors for Taenia solium teniasis and cysticercosis in humans and pigs in a village in Morelos, Mexico. Am J Trop Med Hyg. 1992;46(6):677-685. doi:10.4269/ajtmh.1992.46.677 | Epidemiology | USA | Mexico | 160 | 10.67 |
| 34 | 19 | Montano SM, Villaran MV, Ylquimiche L, et al Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology. 2005;65(2):229-233. doi:10.1212/01.wnl.0000168828.83461.09 | Central nervous system & epilepsy |
Peru | Peru | 160 | 10 |
| 37 | 20 | Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol. 1992;49(3):290-294. doi:10.1001/archneur.1992.00530270106026 | Therapeutics | Brazil | Brazil | 153 | 5.46 |
| 39 | 21 | Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med. 1987;147(4):738-741. | Therapeutics | Mexico | Mexico | 146 | 48.67 |
| 41 | 22 | Brandt JR, Geerts S, De Deken R, et al A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosis. Int J Parasitol. 1992;22(4):471-477. doi:10.1016/0020-7519(92)90148-e. | Diagnosis, laboratory parameters | Belgium | Belgium | 145 | 5.18 |
| 42 | 23 | Terrazas LI, Bojalil R, Govezensky T, Larralde C. Shift from an early protective Th1-type immune response to a late permissive Th2-type response in murine cysticercosis (Taenia crassiceps). J Parasitol. 1998;84(1):74-81. | Immunology | Mexico | Mexico | 144 | 8.47 |
| 43 | 24 | Phiri IK, Ngowi H, Afonso S, et al The emergence of Taenia solium cysticercosis in Eastern and Southern Africa as a serious agricultural problem and public health risk. Acta Trop. 2003;87(1):13-23. doi:10.1016/s0001-706 × (03)00051-2. | Epidemiology | Zambia | Denmark | 144 | 6.55 |
| 44 | 25 | Rosas N, Sotelo J, Nieto D. ELISA in the diagnosis of neurocysticercosis. Arch Neurol. 1986;43(4):353-356. doi:10.1001/archneur.1986.00520040039016 | Diagnosis, laboratory parameters | Mexico | Mexico | 143 | 17.87 |
| 45 | 26 | Bern C, Garcia HH, Evans C, et al Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis. 1999;29(5):1203-1209. doi:10.1086/313470 | Epidemiology | USA | USA | 142 | 6.76 |
| 46 | 27 | Gonzalez AE, Cama V, Gilman RH, et al Prevalence and comparison of serologic assays, necropsy, and tongue examination for the diagnosis of porcine cysticercosis in Peru. Am J Trop Med Hyg. 1990;43(2):194-199. doi:10.4269/ajtmh.1990.43.194 | Epidemiology | Peru | Peru | 142 | 6.76 |
| 48 | 28 | Shandera WX, White AC Jr, Chen JC, Diaz P, Armstrong R. Neurocysticercosis in Houston, Texas. A report of 112 cases. Medicine (Baltimore). 1994;73(1):37-52. doi:10.1097/00005792-199401000-00004 | Clinical presentation | USA | USA | 139 | 5.35 |
| 50 | 29 | Sotelo J, Escobedo F, Penagos P. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol. 1988;45(5):532-534. doi:10.1001/archneur.1988.00520290064015 | Therapeutics | Mexico | Mexico | 137 | 4.28 |